Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects the ODEFSEY label warning that severe acute HBV exacerbations may occur after discontinuation, and it correctly includes the need for close clinical/laboratory monitoring for at least several months with possible anti-HBV therapy.
Category Scores
Accurate Statements
ODEFSEY can cause post-treatment acute exacerbation of hepatitis B.
Supported by Label section 5.1: severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who discontinued products containing FTC and/or TDF, and may occur with discontinuation of ODEFSEY.
Patients should be monitored after discontinuation.
Supported by Label section 5.1: patients who discontinue ODEFSEY should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping.
Possible anti-HBV therapy may be warranted.
Supported by Label section 5.1: if appropriate, anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis.
Unsupported Statements
Contradictions
Important Omissions
The claim does not explicitly state the timeframe 'at least several months' for clinical and laboratory monitoring after stopping ODEFSEY.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim is a direct, label-supported safety warning about monitoring after discontinuation of ODEFSEY in patients with HIV-1/HBV coinfection; while the duration is not explicitly stated, the core safety message is accurate.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Monitoring duration ('at least several months') is not explicitly included.
Suggested Improvement
Add that monitoring should include close clinical and laboratory follow-up for at least several months after discontinuation, consistent with Label section 5.1.